Published on 17/12/2025
WHO PQ for In Vitro Diagnostics: Regulatory Framework
The World Health Organization’s Prequalification (WHO PQ) program for In Vitro Diagnostics (IVDs) has become an essential component of the regulatory framework impacting pharmaceutical and clinical research industries globally. In this article, we will provide a detailed, step-by-step tutorial for regulatory affairs professionals in the pharma sector to navigate the evolving landscape of IVD regulation under WHO PQ updates, particularly those anticipated through 2025.
1. Understanding WHO PQ for In Vitro Diagnostics
The WHO PQ program aims to ensure that IVDs meet international standards of quality, safety, and performance. Regulatory affairs professionals must comprehend the WHO PQ’s functions, which include the assessment of medical devices and diagnostics to foster access to high-quality products for both developed and developing countries.
WHO PQ is particularly important for those involved in pharmaceutical regulatory affairs as it provides a credible mechanism by which manufacturers can demonstrate compliance with global health regulations. With the updated frameworks set to roll out in 2025, professionals in
1.1 Objectives of WHO PQ
- Access and Availability: Enhance the availability of safe and effective IVDs for all populations, particularly underserved ones.
- Quality Assurance: Establish a rigorous assessment process to ensure IVDs meet both safety and performance standards.
- Harmonization of Standards: Promote the convergence of different regulatory frameworks to simplify market access for manufacturers.
1.2 Importance of WHO PQ in Global Regulatory Affairs
WHO PQ is integral for pharmaceutical regulatory affairs because it serves as a benchmark for quality assurance. By aligning with WHO standards, manufacturers can facilitate product approval in various markets, including the EU, US, Canada, India, and Australia. Adhering to these standards can also increase the marketability of devices on a global scale.
2. Regulatory Framework: Step-by-Step Navigation
Understanding the regulatory framework surrounding WHO PQ is essential for professionals in the pharma sector. The following sections outline a step-by-step approach to navigating this complex system.
2.1 Familiarization with WHO Guidelines
The first step in the regulatory framework is to familiarize yourself with the relevant WHO documents. For IVDs, this entails reviewing guidelines and technical reports released by the WHO. These documents provide insights into the evaluation processes and requirements for IVDs seeking WHO PQ status.
2.2 Assessing Market Needs
Conducting a market needs assessment helps determine the type of IVDs that require prequalification. Stakeholders must consider factors like local disease burden, market gaps, and target populations. This assessment will guide manufacturers in understanding how to align their products with WHO PQ objectives.
2.3 Product Development and Quality Management Systems
The quality management system (QMS) must ensure that the IVD is developed in accordance with ISO 13485 and other international standards. This includes conducting risk assessments during the development phase and documenting each stage to maintain compliance. It is essential for regulatory affairs professionals to engage cross-functional teams throughout the product development cycle to uphold high standards.
2.4 Compilation Of Submission Dossier
To initiate the PQ process, manufacturers must compile a comprehensive submission dossier that meets WHO requirements. The dossier should contain:
- Product description and intended use
- Clinical performance data
- Manufacturing process details
- Quality control measures
- Post-market surveillance strategies
2.5 Submission and Review Process
Once the dossier is prepared, it is submitted to the WHO’s PQ team. The review process generally includes a scientific review, assessment of quality control documents, on-site inspections, and sometimes a validation study. Regulatory affairs professionals should plan for possible queries or requests for additional information during this phase.
3. Key Updates and Changes Expected by 2025
By 2025, several key updates are anticipated within the WHO PQ framework that will affect pharmaceutical regulatory affairs in several critical ways:
3.1 Enhanced Data Requirements
As part of the evolving regulatory landscape, it is expected that WHO will implement enhanced data collection requirements. This means more comprehensive clinical trial data will be necessary to substantiate the performance claims of IVDs. Regulatory leaders must ensure they are prepared to collect, analyze, and present this data effectively.
3.2 Digital Transformation of Submission Processes
The integration of digital tools in the IVD submission process is anticipated to streamline evaluations and foster greater transparency. This may include the use of electronic document submissions and digital review platforms. Professionals should familiarize themselves with these upcoming digital platforms to stay ahead of compliance requirements.
3.3 Increased Emphasis on Risk Management
Regulatory agencies are likely to emphasize risk management strategies throughout the product lifecycle, necessitating a proactive approach to identifying and mitigating potential risks associated with IVDs. Regulatory affairs personnel need to implement robust risk management frameworks that align with updated WHO expectations.
4. Practical Actions for Regulatory Affairs Professionals
The upcoming changes in WHO PQ requirements necessitate actionable steps from regulatory affairs teams. Here are some guidelines to consider:
4.1 Continuous Education and Training
Professionals need to engage in continuous education and training regarding the latest WHO guidelines. Participating in workshops, webinars, and industry conferences can help ensure that regulatory affairs teams are well-informed about changes affecting product development and submission processes.
4.2 Cross-Collaboration within Organizations
Regulatory historians and clinical operations need to collaborate closely to align strategies effectively. Creating cross-functional teams that include R&D, operations, marketing, and regulatory affairs will ensure that all aspects of product development are compliant with WHO PQ requirements.
4.3 Regular Monitoring of WHO Updates
Keeping abreast of any changes in WHO guidelines is crucial. Regulatory affairs professionals should regularly monitor the official WHO website for announcements, new publications, and changes to current practices. Reliable platforms like WHO Prequalification can provide essential updates and resources.
5. Conclusion
In conclusion, navigating the WHO PQ framework for In Vitro Diagnostics is essential for regulatory affairs professionals involved in pharmaceutical regulatory affairs. With the imminent changes set for 2025, staying informed and adaptive is critical for ensuring compliance and enhancing patient access to quality diagnostic products globally. By following the structured approach outlined in this article, organizations can position themselves strategically within the regulatory landscape of IVDs, thereby facilitating market access and improving health outcomes.